Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy

被引:5
|
作者
Tong, Yi Tat [1 ]
Lai, Zongshan [1 ]
Katz, Matthew H. G. [2 ]
Prakash, Laura R. [2 ]
Wang, Hua [3 ]
Chatterjee, Deyali [1 ]
Kim, Michael [2 ]
Tzeng, Ching-Wei D. [2 ]
Lee, Jeffrey E. E. [2 ]
Ikoma, Naruhiko [2 ]
Rashid, Asif [1 ]
Wolff, Robert A. [3 ]
Zhao, Dan [3 ]
Koay, Eugene J. [4 ]
Maitra, Anirban [1 ,5 ]
Wang, Huamin [1 ,5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
pancreatic cancer; neoadjuvant therapy; FOLFIRINOX; gemcitabine/nab-paclitaxel; tumor response grade; tumor stage; lymph node metastasis; survival; PREDICTS POOR-PROGNOSIS; NAB-PACLITAXEL; CANCER; SURVIVAL; PANCREATICODUODENECTOMY; CHEMORADIATION; INVASION;
D O I
10.3390/cancers15092608
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant FOLFIRINOX and gemcitabine/nab-paclitaxel (GemNP) therapies are increasingly used to treat patients with pancreatic ductal adenocarcinoma (PDAC). However, limited data are available on their clinicopathologic prognosticators. We examined the clinicopathologic factors and survival of 213 PDAC patients who received FOLFIRINOX with 71 patients who received GemNP. The FOLFIRINOX group was younger (p < 0.01) and had a higher rate of radiation (p = 0.049), higher rate of borderline resectable and locally advanced disease (p < 0.001), higher rate of Group 1 response (p = 0.045) and lower ypN stage (p = 0.03) than the GemNP group. Within FOLFIRINOX group, radiation was associated with decreased lymph node metastasis (p = 0.01) and lower ypN stage (p = 0.01). The tumor response group, ypT, ypN, LVI and PNI, correlated significantly with both DFS and OS (p < 0.05). Patients with the ypT0/T1a/T1b tumor had better DFS (p = 0.04) and OS (p = 0.03) than those with ypT1c tumor. In multivariate analysis, the tumor response group and ypN were independently prognostic factors for DFS and OS (p < 0.05). Our study demonstrated that the FOLFIRINOX group was younger and had a better pathologic response than the GemNP group and that the tumor response group, ypN, ypT, LVI and PNI, are significant prognostic factors for survival in these patients. Our results also suggest that the tumor size of 1.0 cm is a better cut off for ypT2. Our study highlights the importance of systemic pathologic examination and the reporting of post-treatment pancreatectomies.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Sarcopenia Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel
    Asama, Hiroyuki
    Ueno, Makoto
    Kobayashi, Satoshi
    Fukushima, Taito
    Kawano, Kuniyuki
    Sano, Yusuke
    Tanaka, Satoshi
    Nagashima, Shuhei
    Morimoto, Manabu
    Ohira, Hiromasa
    Maeda, Shin
    PANCREAS, 2022, 51 (02) : 148 - 152
  • [32] Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with localized pancreatic ductal adenocarcinoma (PDAC)
    Becerra, Carlos
    Paulson, Andrew Scott
    Cavaness, Keith M.
    Celinski, Scott A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [33] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [34] Pathologic and clinical outcomes after neoadjuvant modified FOLFIRINOX and gemcitabine and NAB-paclitaxel for pancreatic cancer.
    Markabawi, Danny
    Ianiro, Cora
    Burton, Jeffrey
    Bolton, Nathan
    Mizrahi, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16236 - E16236
  • [35] First-line chemotherapies with FOLFIRINOX or gemcitabine plus nab-paclitaxel for unresectable pancreatic ductal adenocarcinoma in Japanese daily clinical practice
    Yano, M.
    Terashima, T.
    Yamashita, T.
    Miyazawa, M.
    Mizuno, H.
    Nomura, Y.
    Omura, H.
    Takata, Y.
    Ooishi, N.
    Shugo, H.
    Yamada, K.
    Takabatake, H.
    Takatori, H.
    Hodo, Y.
    Nishino, R.
    Hayashi, T.
    Mizukoshi, E.
    Kaneko, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [37] Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis
    Hiroki Irie
    Rei Suzuki
    Tadayuki Takagi
    Mitsuru Sugimoto
    Naoki Konno
    Yuki Sato
    Takuto Hikichi
    Jun Nakamura
    Minami Hashimoto
    Hiromasa Ohira
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 517 - 523
  • [38] Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis
    Irie, Hiroki
    Suzuki, Rei
    Takagi, Tadayuki
    Sugimoto, Mitsuru
    Konno, Naoki
    Sato, Yuki
    Hikichi, Takuto
    Nakamura, Jun
    Hashimoto, Minami
    Ohira, Hiromasa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 517 - 523
  • [39] Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study
    Queck, Alexander
    Elango, Sharra
    Koch, Christine
    Walter, Dirk
    Schmidt, Jennifer
    Trebicka, Jonel
    Trojan, Joerg
    Pession, Ursula
    Finkelmeier, Fabian
    Waidmann, Oliver
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (03) : 79 - 86
  • [40] Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
    Sonia Zaibet
    Vincent Hautefeuille
    Edouard Auclin
    Astrid Lièvre
    David Tougeron
    Mathieu Sarabi
    Marine Gilabert
    Julie Wasselin
    Julien Edeline
    Pascal Artru
    Dominique Bechade
    Clémence Morin
    Agnes Ducoulombier
    Julien Taieb
    Simon Pernot
    British Journal of Cancer, 2022, 126 : 1394 - 1400